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Streptococcus suis is a pathogen with serious economic effects 
on the pig industry worldwide. The disease is endemic in adult 
pigs in most countries where pig farming is common. Infections 
in adult pigs are usually asymptomatic, but infant piglets that 
get infected through contact with colonized adult females 
can develop fatal sepsis. Transmission to humans is rare and 
generally restricted to individuals with occupational exposure 
to live or dead pigs. The ﬁ  rst human case of S. suis infection 
was reported in Denmark in 1968. Most of the approximately 
200 previously reported human cases were characterized by 
meningitis and septicemia, and associated with a mortality of 
less than 10%. 
Now George Gao and colleagues from the Chinese Academy 
of Sciences, the Chinese Center for Disease Control and 
Prevention, and other Chinese institutions report details of a 
recent unusual outbreak in 2005 of S. suis that affected over 200 
individuals in Sichuan province and killed 38 of them. Besides 
the large number of individuals infected and the high mortality 
rate, it was the clinical symptoms associated with this outbreak 
that attracted interest and worry from scientists and health 
ofﬁ  cials worldwide when the outbreak was ﬁ  rst reported in the 
news last year. 
As Gao and colleagues now detail in their article, a large 
proportion of the individuals infected (including all but one 
of the patients who died) showed symptoms of streptococcal 
toxic shock syndrome (STSS). Up to now, most reported cases 
of STSS had been attributed to group A streptococci. However, 
as Gao and colleagues show, the etiologic agents in the recent 
outbreak, as well as in an earlier outbreak in Sichuan province 
in 1998 that killed 14 of 25 reported patients, were clearly of 
the serotype 2 strains of S. suis. Both human outbreaks were 
closely linked to outbreaks in the local pig populations, and the 
researchers report that there are no reasons to believe that any 
of the cases had been caused by human-to-human transmission. 
They also showed that S. suis isolated from the human patients 
caused typical S. suis disease in newborn piglets. 
Were there other unusual characteristics among the Chinese 
isolates that could explain their ability to cause STSS? STSS 
is thought to be caused by bacterial superantigens that 
overstimulate the human immune system. Gao and colleagues 
tested the S. suis isolates associated with STSS for superantigen 
production, but were unable to detect any. 
One of the key questions that arose when the recent outbreak 
was ﬁ  rst reported was whether a new and more virulent strain 
of S. suis has emerged in China. Gao and colleagues performed 
an initial genomic survey of the isolates from the Chinese 
outbreaks to look for unusual characteristics that could explain 
the virulence of the pathogens. They did ﬁ  nd some differences 
between the isolates from the 1998 and 2005 Chinese outbreaks 
(which appear very similar to each other) and other virulent 
strains, but a more detailed sequence analysis and functional 
studies will be needed before it is clear whether any of these 
differences have functional consequences for pathogenesis in 
pigs or humans. 
In an accompanying Perspective article (DOI: 10.1371/
journal.pmed.0030187), Shiranee Sriskandan and Joshua Slater 
suggest that S. suis infection “should now be in the list of 
differential diagnoses when clinicians encounter patients with 
unexplained sepsis who have a history of exposure to pigs.” 
They conclude that “the emergence of any new zoonotic disease 
associated with high mortality is of global concern” and call for 
“international collaboration … to clarify differences between 
isolates circulating in different regions of the world.” 
Tang J, Wang C, Feng Y, Yang W, Song H, et al. (2006) Streptococcal 
toxic shock syndrome caused by Streptococcus suis Serotype 2. DOI: 
10.1371/journal.pmed.0030151
Streptococcus suis Outbreak with Symptoms of Toxic Shock Syndrome in China
DOI: 10.1371/journal.pmed.0030218
Throughout life, the body’s tissues are 
maintained and repaired by stem cells—
self-renewing cells that differentiate 
into many mature cell types. Every day, 
for example, the human body makes 
billions of white blood cells, red blood 
cells, and platelets from hematopoietic 
(blood system) stem cells (HSCs) to 
replace cells lost by normal wear and 
tear. This process of hematopoiesis helps 
to maintain a healthy immune system, 
enables sufﬁ  cient oxygen to be carried 
around the body, and ensures effective 
blood clotting after wounding. 
Some people, however, do not have a 
fully functioning hematopoietic system. 
They may have been born with a genetic 
alteration that disrupts the function 
of some blood cells, or they may have 
had chemotherapy for cancer that has 
destroyed their hematopoietic system. 
One way to help such people, who are 
often prone to infection, is to provide 
them with a new supply of HSCs through 
transplantation. HSCs are found in 
small numbers in the bone marrow and 
peripheral blood, as well as cord blood, 
which is harvested from the umbilical 
cord at birth. Cord blood is increasingly 
being used to treat hematopoietic 
disorders, but the low number of HSCs 
present in a unit of cord blood means 
that transplanted cells can be slow to 
establish themselves (or engraft) in an 
adult recipient, prolonging the time 
the patient is susceptible to infections. 
Consequently, researchers are looking 
for ways to encourage HSC expansion 
before transplantation. Xiao-Bing Zhang, 
Hans-Peter Kiem and colleagues now 
Hematopoietic Stem Cell Expansion: Testing the Potential of HOXB4 in Nonhuman Primates
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report that overexpression of a stem 
cell self-renewal gene called HOXB4 
in HSCs improves their expansion 
and engraftment in a nonhuman 
primate model, particularly early after 
transplantation. 
Overexpression of human HOXB4 in 
mouse HSCs is known to induce their ex 
vivo expansion without compromising 
their ability to differentiate. It 
also encourages the expansion of 
hematopoietic precursor cells from 
human cord blood, both in culture and 
when transplanted into mice. However, 
because immunodeﬁ  cient mice do 
not support the differentiation of all 
human hematopoietic lineages, they 
are not an ideal model in which to 
investigate human HSC transplantation. 
Zhang, Kiem, and colleagues, therefore, 
turned to nonhuman primates, a well-
established preclinical model for HSC 
transplantation and gene therapy, to 
investigate further whether treatment 
with HOXB4 holds promise for HSC 
expansion before transplantation. 
The researchers ﬁ  rst isolated CD34+ 
cells from six experimental animals—
CD34 is a protein that is expressed only 
by lymphoid and myeloid hematopoietic 
precursor cells, which together 
differentiate into all the different blood 
cells. Next, the researchers split the 
CD34+ cells from each animal into two 
batches. One batch was treated with 
a retrovirus expressing HOXB4 tagged 
with a green ﬂ  uorescent protein marker 
(HOXB4GFP+); the control batch was 
treated with a retrovirus expressing a 
yellow ﬂ  uorescent protein marker (YFP+). 
Three or nine to 12 days later, the batches 
of cells were mixed and transplanted 
back into their respective donor animals, 
whose hematopoietic system had in the 
meantime been destroyed by irradiation. 
The researchers then tracked the labeled 
cells as they repopulated the animals.
Zhang, Kiem, and colleagues showed 
that, in this competitive repopulation 
assay, HOXB4 overexpression greatly 
improved the engraftment of CD34+ 
cells, particularly when the cells were 
expanded ex vivo for an additional six 
to nine days before transplantation. 
Short-term engraftment (two weeks 
after transplantation) of HOXB4GFP+ 
cells was up to 56-fold higher than that 
of YFP+ cells. Over time, the percentage 
of HOXB4-expressing cells in the 
animals’ blood declined, but remained 
higher than the percentage of control 
cells even after six months, suggesting 
that HOXB4 overexpression might also 
improve long-term engraftment. Finally, 
the researchers report that three and six 
months after transplantation both the 
myeloid and lymphoid hematopoietic 
lineages contained HOXB4GFP+ and 
YFP+ cells. HOXB4GFP+ cells were more 
common in the myeloid lineage than 
YFP+ cells, but in lymphocytes the pattern 
was reversed, indicating that HOXB4 
overexpression may have a larger effect 
on the engraftment and differentiation 
of myeloid precursors than of lymphoid 
precursors.
These results suggest that HOXB4-
mediated ex vivo expansion of stem 
cells could be one way to accelerate 
the engraftment of HSCs from sources 
that contain limited numbers of stem 
cells (such as cord blood). Because only 
small numbers of animals were used 
in this proof-of-principle study, more 
experiments will be needed before it 
is clear whether HOXB4 can be used to 
improve the expansion and engraftment 
of CD34+ cells in patients whose 
hematopoietic system has failed. As the 
researchers point out, the availability of 
recombinant HOXB4 protein makes it 
possible to treat HSCs directly, without 
the potential problems associated with 
genetic manipulation of the cells. 
Zhang XB, Beard BC, Beebe K, Storer B, 
Humphries RK, et al. (2006) Differential 
effects of HOXB4 on nonhuman primate 
short- and long-term repopulating cells. 
DOI: 10.1371/journal.pmed.0030173
The 2002 SARS outbreak that started in China spread quickly 
to Hong Kong, Singapore, Vietnam, and Canada. Although 
the 774 people it killed was a small number compared with 
the global death toll from other infectious diseases, the 
outbreak caused widespread panic because of the lack of 
global preparedness for what could have become a worldwide 
epidemic. Since then, surveillance and monitoring systems have 
been put into place and existing ones strengthened, but since 
another outbreak is always possible, researchers around the 
globe are still devoting much time to studying the infection. 
Analyzing the disease in animals to investigate the pathogenesis 
of the novel coronavirus that causes SARS (SARS-CoV) is crucial 
to developing vaccines and treatments to tackle the next 
epidemic. 
In adults, SARS ﬁ  rst causes ﬂ  u-like symptoms, then lower 
respiratory tract disease, and ﬁ  nally severe respiratory disease. 
But despite having similar levels of viral replication, children tend 
to have milder symptoms. They do not get chills or myalgias, nor 
do they need help breathing, as adults tend to need toward the 
end of the illness.
Several animals—mice, cats, and ferrets—have been tested 
to see whether they can support replication of SARS-CoV, 
and others—civets and wild bats—have been investigated as 
potential viral reservoirs. In studies on nonhuman primates, the 
focus has been to document histopathological disease rather 
A Macaque Model of SARS
DOI: 10.1371/journal.pmed.0030222
DOI: 10.1371/journal.pmed.0030222.g001
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than to look for more advanced symptoms such as radiographic 
evidence of pulmonary disease, as happens in humans.
In a new study, Jason Paragas, James Lawler, and colleagues 
now describe what happened when they infected eight 
macaques with the SARS-CoV Urbani strain; four in the nasal 
cavities and bronchus; two in the nasal cavities and conjunctiva; 
and two intravenously.
Although all animals had evidence of viral replication 
and produced neutralizing antibodies, none of the animals 
developed fever, and only those in the ﬁ  rst two groups had 
mild-to-moderate symptoms (decreased activity and feeding, 
and slightly labored breathing). By contrast, the animals that 
had been intravenously infected showed no clinical symptoms. 
When tested for the presence of the virus, all animals had viral 
DNA in nasal swabs and urine samples—irrespective of how 
they had been infected. Paragas and colleagues also took chest 
radiographs of six of the animals—never before done in any 
SARS-CoV study on nonhuman primates. Three nonhuman 
primates showed signs of pneumonia by radiographs.
More interesting ﬁ  ndings came from the fact that some 
animals were infected with wild-type virus, and others with a 
recombinant infectious clone. All developed similar disease, 
indicating that it was just the SARS-CoV that was responsible 
for disease, and that no coinfection was required, as has been 
suggested by some workers. In addition, six animals that were 
reinfected with SARS-CoV 13 weeks after the ﬁ  rst infection 
were immune—importantly, two of these had initially had the 
recombinant virus, which means that the molecular clone could 
induce protection against the wild-type form. 
Paragas and colleagues’ work differs from previous studies of 
SARS-CoV in nonhuman primates. Some researchers found more 
severe clinical disease; others, no overt disease at all. Tests on 
African green monkeys showed that one monkey had fever on 
the third day after infection. These differences could have been 
because of the strain, the dose, or the route of infection.
Ultimately, disease in nonhuman primates is far milder than 
that in adult humans. What is interesting is that it is similar to 
SARS-CoV infection in human children. The researchers suggest 
that the key to the difference in disease severity could lie in the 
fact that adult humans with SARS-CoV have far higher levels of 
inﬂ  ammatory cytokines than do children, or, as this research 
suggests, nonhuman primates.
Lawler JV, Endy TP, Hensley LE, Garrison A, Fritz EA, et al. (2006) 
Cynomolgus macaque as an animal model for severe acute respiratory 
syndrome. DOI: 10.1371/journal.pmed.0030149
Leishmaniases are parasitic diseases 
that are endemic (constantly present) in 
many tropical and temperate countries. 
Every year, 2 million people become 
infected with one of 20 pathogenic 
species of Leishmania through the bites 
of infected female sand ﬂ  ies. These pick 
up parasites by biting an infected animal 
(zoonotic transmission) or an infected 
person (anthroponotic transmission). In 
their human host, Leishmania parasites 
reproduce inside macrophages—
white blood cells that usually kill 
microorganisms, clear up cellular 
debris, and activate other immune 
cells. When the macrophages are full of 
parasites, they burst—this destruction 
causes the symptoms associated with 
leishmaniases—and the released 
parasites infect further macrophages.
In cutaneous leishmaniasis—the most 
common form of the disease—patients 
develop skin ulcers a few weeks after 
being bitten by infected sand ﬂ  ies. 
These usually heal spontaneously but 
leave ugly, sometimes disabling, scars. 
Cutaneous Leishmania infections can 
spread to the nose or mouth to cause 
mucocutaneous leishmaniasis, which 
destroys the sensitive linings of these 
organs. Cutaneous and mucocutaneous 
leishmaniases are not life-threatening 
in themselves, but patients can develop 
fatal secondary infections. Visceral 
leishmaniasis, which affects the spleen 
and other internal organs, is often fatal if 
untreated. 
Leishmaniases are usually treated 
with pentavalent antimony-containing 
drugs, such as meglumine antimoniate 
(Glucantime), but patients are becoming 
increasingly unresponsive to these drugs. 
In India, for example, more than 60% of 
cases of visceral leishmaniasis do not 
respond to treatment. Unresponsiveness 
can be caused by the parasite developing 
drug resistance, by changes in the host’s 
immunological status, or by suboptimal 
treatment regimens. Ramtin Hadighi, 
Mehdi Mohebali, Marc Ouellette, and 
colleagues have been investigating 
whether the increased incidence of 
Glucantime-unresponsive cutaneous 
leishmaniasis in Iran correlates with 
parasite resistance to the drug. They 
now report that treatment failure 
for cutaneous leishmaniasis in Iran, 
like the treatment failure seen for 
visceral leishmaniasis in India, is due to 
Glucantime-resistant parasites.
The researchers isolated Leishmania 
parasites from 185 skin lesions from 
untreated patients living in Mashhad, 
a region of Iran where anthroponotic 
cutaneous leishmania is endemic. Of 
these patients, 20 did not respond to 
Glucantime—their skin ulcers failed 
to heal. To ﬁ  nd out if this was due to 
drug-resistant parasites, the researchers 
infected mouse macrophages with 
all 185 isolates and then treated the 
infected cells with Glucantime. Several 
days later, the parasites surviving inside 
the cells were stained with a dye and 
then counted using a microscope. The 
researchers report that although initial 
infection rates were similar, parasites 
from the unresponsive patients were 
Drug-Resistant Leishmania tropica Parasites Detected in Iranian Cutaneous Leishmaniasis
DOI: 10.1371/journal.pmed.0030230 
DOI: 10.1371/journal.pmed.0030230.g001
 Female  sandﬂ  ies transmit the Leishmania 
parasite 
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The World Health Organization estimates that malaria kills 
an African child every 30 seconds. Many of these children die 
because they develop severe anemia (a deﬁ  ciency of red blood 
cells). As many as 5 million cases of severe malarial anemia occur 
in African children every year, and 13% of these cases are fatal. 
Turning the statistics around, more than half of young children in 
African countries where malaria is endemic (constantly present) 
are anemic. Nutritional deﬁ  ciencies and various infections 
account for some of this disease burden, but malaria is one of 
the most important factors contributing to anemia.
The malaria parasite destroys red blood cells (a process 
called hemolysis) as part of its life cycle, releasing hemoglobin 
(Hb)—an iron-containing protein that carries oxygen around 
the body—into the circulation. Free Hb can cause oxidant stress, 
which is itself associated with anemia in malaria. An important 
modulator of such stress is a serum protein called haptoglobin 
(Hp), which captures Hb during hemolysis.
Hp exists in three molecular forms that are genetically 
determined by two variants (alleles) of a single gene. People 
who have two copies of the Hp1 allele make only Hp1-1, a 
homodimeric protein. People with two copies of the Hp2 allele 
(the Hp2/2 genotype) make Hp2-2, a large circular polymer, and 
those with one copy of each allele make the linear polymer Hp1-2 
in addition to these two forms. The functional properties of the 
three Hp forms are somewhat different. In particular, Hp2-2 binds 
Hb much less tightly than the other forms. Sarah Atkinson and 
her colleagues reasoned, therefore, that the Hp2/2 genotype might 
be a risk factor for anemia in children in malaria-endemic areas. 
To test their hypothesis, they measured Hb levels in Gambian 
children at the start and end of the malaria season, and now 
report in a new study that, as predicted, the Hp2/2 genotype is 
associated with seasonal childhood anemia in this population.
Most cases of malaria in The Gambia occur between 
September and December, so the researchers recruited 780 
children aged two to six years from ten Gambian villages in July 
2001, determined their Hp genotypes, assessed their blood Hb 
and serum Hp concentrations and iron status, and determined 
whether they were infected with malaria parasites. These 
variables were re-measured at the end of the malaria season. 
In addition, the researchers determined two other genetic 
polymorphisms that might inﬂ  uence Hb levels over the malaria 
Childhood Anemia in a Malaria-Endemic Region: The Haptoglobin Genotype Connection
DOI: 10.1371/journal.pmed.0030227
DOI: 10.1371/journal.pmed.0030227.g001
   Bed nets are essential in malaria-endemic regions such as The Gambia 
resistant to intermediate or high levels of 
Glucantime. On average, parasites from 
unresponsive patients were 4-fold less 
susceptible to Glucantime than parasites 
from responsive patients.
Next, the researchers partly 
characterized the 20 drug-resistant 
parasite isolates and 11 drug-susceptible 
isolates. By sequencing the gene for the 
metabolic enzyme pteridine reductase 
1, the researchers discovered that 
28 of the isolates were L. tropica; the 
remaining three were L. major. Only one 
unresponsive isolate was L. major; the 
rest were L. tropica. The researchers also 
used pulsed-ﬁ  eld gel electrophoresis 
to separate and study Leishmania 
chromosomes. Because these evolve 
quickly, the chromosome composition 
(karyotype) of different isolates indicates 
their genetic relatedness. The L. major 
isolates formed one group using this 
technique but the L. tropica isolates 
fell into three distinct groups, each 
of which included drug-susceptible 
isolates and isolates with intermediate 
and high Glucantime resistance. In 
other words, susceptible and resistant 
isolates were often closely related. 
Finally, the researchers conﬁ  rmed the 
drug sensitivity of several closely related 
strains by testing their ability to grow 
in a human monocyte cell line in the 
presence of Glucantime, and also showed 
that drug resistance was stable over 
time in resistant isolates but could be 
reversed by treatment with an inhibitor 
of glutathione biosynthesis. This last 
result indicates that thiols (molecules 
containing a sulphur atom bonded to 
a hydrogen atom) may be important 
for the resistant phenotype, and may 
suggest a way to reverse drug resistance.
Overall, these results provide the ﬁ  rst 
evidence that Leishmania parasites can 
acquire drug resistance that contributes 
to treatment failure in cutaneous 
leishmaniasis. They also indicate that 
Glucantime-resistant L. tropica isolates 
are now frequent in Iran. Additional work 
is needed to understand the nature of 
the resistance mechanisms, with the goal 
to improve diagnosis and treatment of 
resistant leishmaniasis. 
Hadighi R, Mohebali M, Boucher P, 
Hajjaran H, Khamesipou A, et al. (2006) 
Unresponsiveness to Glucantime treatment 
in Iranian cutaneous leishmaniasis due to 
drug resistant Leishmania tropica parasites. 
DOI: 10.1371/journal.pmed.0030162
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Over the course of human history, 
hundreds of thousands of genetic 
mutations have arisen in the global 
population. The most harmful ones 
usually disappear—by affecting an 
individual’s “ﬁ  tness,” i. e., the ability 
to reproduce, the mutations are lost 
before carriers can pass them on to their 
children—whereas most mutations are 
maintained in the population in low 
frequencies. Some mutations, however, 
can give the carrier such a large survival 
advantage that the mutations become 
positively selected for, leading to their 
presence in high frequencies in some 
populations. 
Blood disorders are a good example 
of this selection process. The sickle cell 
mutation, for example, is a mutation 
of the β-globin gene that can cause 
severe anemia in people who inherit 
two mutated genes. People with just 
one mutated hemoglobin (Hb) S gene, 
however, can be highly protected against 
malaria. And in Africa, where malaria is 
one of the biggest killers, up to 40% of 
people are believed to carry one of the 
sickle genes.
The thalassemias are also inherited 
blood disorders that result from 
mutations in either the α-globin or β-
globin genes. α-thalassemias are now 
the most common genetic disorders of 
human beings, and this is thought to be 
because of their protective effect against 
malaria. People usually have four α-
globin genes, two on each Chromosome 
16. In Africa, however, a common 
deletion can remove one of these genes 
from either chromosome or from both 
chromosomes; individuals with three 
or two α-globin genes remaining have 
anemia, which is more severe the fewer 
α-globin genes are present but is not 
life-threatening. This condition, in which 
at most one α-globin gene is missing 
from each chromosome, is known as 
α+-thalassemia (α0-thalassemia occurs 
when both genes are removed from a 
chromosome). Despite the well-known 
beneﬁ  cial effect of α+-thalassemia 
against malaria, scientists know little 
about how exactly the α+-thalassemias 
result in this protection, and whether 
they protect against all forms of the 
disease.
In a new study in PLoS Medicine, 
Thomas Williams, Sammy Wambua, 
and colleagues—researchers from 
Kenya and Oxford—investigated the 
effect of α+-thalassemia on malaria 
and other childhood diseases, such 
as gastroenteritis, in two groups of 
children in Kenya. The ﬁ  rst group 
comprised children younger than ﬁ  ve 
years old, recruited between September 
1998 and August 2001, 301 of whom 
were analyzed in the study (the mild 
disease cohort). The second group 
comprised 2,104 children recruited 
at birth between May 1992 and April 
1995 (the birth cohort). All children 
analyzed were typed for both HbS and 
α+-thalassemia. 
Williams and colleagues found that 
α+-thalassemia (either with one or two 
α-globin genes lost) was associated 
with signiﬁ  cant reductions in the rate 
of admission to hospital with malaria 
(with or without signs of severity) and 
severe malaria. Both homozygous 
individuals (with two α genes missing 
in total, one from each chromosome) 
and heterozygote individuals (with only 
one α gene missing in total) had much 
lower rates of severe malaria anemia than 
normal children.
However, α+-thalassemia had no effect 
on symptomless parasitemia (deﬁ  ned 
as the presence of the Plasmodium 
falciparum malaria parasite in the blood 
of a child, but without fever or other 
symptoms). And although the occurrence 
of uncomplicated malaria was lower 
in both those heterozygous and those 
homozygous for α+-thalassemia compared 
with normal children, this drop in 
incidence was not statistically signiﬁ  cant. 
In general, there were no links 
between α+-thalassemia and the 
occurrence of nonmalarial illnesses. There 
were, however, two exceptions. In the 
birth cohort, fewer heterozygous infants 
than normal children were admitted 
to hospital with severe anemia. In the 
mild disease cohort, both heterozygous 
and homozygous children had a lower 
frequency of lower respiratory tract 
infections than normal children—
although, this was not seen in the other 
cohort.
α+-Thalassemia and Protection from Malaria
DOI: 10.1371/journal.pmed.0030221
season—an Hb variant that causes sickle cell anemia (HbS), 
and glucose-6 phosphate dehydrogenase (G6PD) gene variants 
associated with hemolytic anemia. 
Atkinson and her colleagues ﬁ  rst analyzed their study 
population in terms of their Hp genotype. This univariate 
(single) analysis included 671 children—a few children were not 
included because of incomplete data. Baseline hb levels were 
not affected by Hp genotype, but the average drop in hb was 
8.9 g/l in the 17% of children with the Hp2/2 genotype compared 
with only 5.1 g/l in children with the other genotypes. By 
contrast, the magnitude of the drop in Hb levels over the season 
was not affected by HbS or G6PD genotype—two other genetic 
traits that affect the red blood cells. Because multiple factors 
inﬂ  uence Hb concentrations (for example, recent infection with 
malarial parasites and iron status), the researchers also did a 
multiple regression analysis of their data to test the effect of all 
such factors on Hb levels at the end of the malaria season. There 
were 565 children who had data complete enough for this more 
detailed analysis, and, once again, the Hp genotype emerged as 
a risk factor for anemia, even after adjusting for other factors that 
affect Hb levels. 
Atkinson and her colleagues suggest that the association 
between Hp genotype and seasonal childhood anemia may 
reﬂ  ect the reduced ability of the Hp2-2 polymer to scavenge free 
Hb and its bound iron after malaria-induced hemolysis. They 
also discuss why Hp2, a potentially detrimental allele, should be 
common in The Gambia, where malaria is endemic. Hp2 arose 
from Hp1 about 2 million years ago, and its subsequent spread 
across the world seems to have been driven by a strong genetic 
pressure, such as exposure to a life-threatening disease. The 
authors suggest that malaria may be one of the diseases that 
helped to select for the Hp2 allele; it is possible that the Hp2 allele 
may provide protection from life-threatening malaria, albeit at 
the expense of impaired hematological recovery from mild and 
asymptomatic malaria. In a related Perspective (DOI: 10.1371/
journal.pmed.0030200), Stephen Rogerson expands on the 
possible mechanisms of Hp-related anemia, and considers what 
the wider health implications of this study might be.
Atkinson SH, Rockett K, Sirugo G, Bejon PA, Fulford A, et al. (2006) 
Seasonal childhood anaemia in West Africa is associated with the 
haptoglobin 2-2 genotype. DOI 10.1371/journal.pmed.0030172
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These ﬁ  ndings appear to contradict 
previous results from a study conducted 
by the same group in the Paciﬁ  c islands 
of Vanuatu that showed α+-thalassemia 
might increase the frequency of 
uncomplicated malaria. The authors say 
this might partly be explained by the fact 
that, unlike Kenya, in Vanuatu two species 
of malaria, P. vivax and P. falciparum, 
both cause disease at similar frequencies. 
Furthermore, there may be major genetic 
differences in both human and parasite 
populations between these regions.
Whether the mutation has a 
protective effect against other 
diseases is still unresolved. The 
authors maintain that such an effect 
is plausible—indeed, the protection 
from lower respiratory tract infections 
in some children was of a similar 
magnitude to that for malaria. The 
authors have also previously recorded 
protection against nonmalarial diseases 
in Papua New Guinea.
These ﬁ  ndings have important 
implications for researchers looking 
for “antimalarial” genes and for 
those searching for potential vaccine 
candidates: they will need to use 
a carefully focused approach that 
differentiates between uncomplicated, 
or symptomless, disease and the 
complicated, or severe, form.
Wambua S, Mwangi TW, Kortok M, Uyoga 
SM, Macharia AW, et al. (2006) The effect 
of α+-thalassaemia on the incidence of 
malaria and other diseases in children 
living on the coast of Kenya. DOI: 10.1371/
journal.pmed.0030158
Until the mid-20th century, malaria occurred in most 
temperate, subtropical, and tropical countries of the world. Then, 
the introduction of powerful insecticides, including DDT, made 
it possible to eliminate this human parasitic disease in many 
temperate countries by controlling the mosquitoes that transmit 
malarial parasites between people. Elsewhere, eradication efforts 
were less successful, but the use of inexpensive antimalarial 
drugs such as chloroquine and sulfadoxine-pyrimethamine (SP) 
further reduced global morbidity and mortality from malaria. 
Sadly, the rapid spread of resistance to chloroquine (and more 
recently to SP) has resulted in a resurgence of malaria over the 
past three decades. Nowadays, 40% of the world’s population 
is at risk of contracting malaria, and every year, it kills at least 
1 million people—mainly children. Pregnant women and their 
unborn children are particularly vulnerable to malaria, for whom 
it is a major cause of perinatal mortality, low birth weight, and 
maternal anemia. 
One way to reduce malaria morbidity and mortality is to 
treat asymptomatic individuals, regardless of their infection 
status, with regular therapeutic doses of antimalarial drugs. 
Intermittent preventative (or presumptive) treatment (IPT) 
is currently used in pregnant women (IPTp) in malaria-
endemic areas, and IPT for infants (IPTi) is also being 
considered. However, before an intervention of this type 
is widely introduced, its potential impact on the spread of 
drug-resistant parasites needs to be investigated. A badly 
designed intervention could increase the speed at which 
malaria parasites become resistant to new drugs, an outcome 
that public health ofﬁ  cials want to avoid. Ideally, such 
information would come from ﬁ  eld trials, but in practice such 
trials are rarely undertaken, so researchers, including Wendy 
Prudhomme O’Meara, David Smith, and Ellis McKenzie, have 
turned instead to mathematical modeling. O’Meara and 
colleagues now describes a model that has allowed them to 
evaluate the possible impact of IPTp and IPTi on the spread of 
drug-resistant malaria parasites. Their analysis highlights the 
importance of carefully choosing which drugs to use for IPTi, 
and indicates which conditions are most likely to encourage 
the spread of drug resistance.
Drug use patterns—how quickly the body removes each drug, 
how well an individual’s immune response deals with malaria 
parasites, and how often each person gets bitten by an infected 
mosquito (the transmission intensity)—all affect the spread of 
drug-resistant parasites. Prudhomme O’Meara and colleagues 
built these factors into a composite model that incorporates a 
human and a parasite population model. They then used their 
model to predict the potential for drug-resistant parasites to 
spread in low- and high-transmission settings, and to predict 
how the use of IPT in adults and infants, the time taken for 
drug elimination, and the treatment of infections (instead of 
asymptomatic individuals alone) might affect the spread of drug 
resistance.
One prediction of their model is that whereas fully resistant 
parasites (which can survive a full therapeutic dose of an 
antimalarial drug) are more likely to spread under conditions 
of high transmission, partially resistant parasites (which 
survive at intermediate drug concentrations) are more likely 
to spread in low-transmission areas, a result supported by 
epidemiological observations. The model also predicts that the 
use of a drug for IPT to which there is no existing resistance 
in a high-transmission area will accelerate the appearance of 
partial resistance, followed by an explosion of full resistance. 
Another analysis indicates that drugs that are rapidly 
eliminated from the body (e.g., chlorproguanil-dapsone) 
may be preferable to those that linger (e.g., SP). This latter 
type of drug maximizes the period of protection from each 
treatment but also maximizes the time when enough drug is 
present to allow selection of resistant parasites (the window 
for selection). Finally, comparing IPTp with IPTi, the model 
predicts that partially resistant parasites will spread faster 
when IPT is given to infants (who have little or no immunity to 
malaria) than when given to adults (who often are immune to 
some degree).
The researchers stress that their model provides a qualitative, 
not a quantitative, assessment of how partial and fully resistant 
malaria parasites will spread in different communities under 
different drug use strategies. But, they say, the model can be 
used as a tool to determine the critical questions that need to 
be addressed before broad implementation of IPT. In particular, 
they note, their model highlights the importance of carefully 
selecting the drug to be used in IPTi programs in different 
settings so that protection is maximized while minimizing the 
chances of antimalarial drug resistance emerging.
Prudhomme O’Meara W, Smith DL, McKenzie FE (2006) Potential 
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Each year, nearly 500,000 new cases of cervical cancer are 
diagnosed around the world, and more than 250,000 women 
die from the disease. Most of these cases occur in developing 
countries where there is no routine screening for precancerous 
lesions. By contrast, in developed countries, national screening 
programs have greatly reduced the number of women dying 
from this cancer—between 1955 and 1992 in the US, for 
example, cervical cancer deaths dropped by 74%.
Infection with a sexually transmitted human papillomavirus 
(HPV) is a precondition for the development of cervical cancer. 
Of the 35 HPV types that can infect the genital tract, about 
half have oncogenic potential—the rest cause benign warts. 
The immune system clears most HPV infections but persistent 
infection with HPV type 16 accounts for approximately 55% of 
cervical cancers. Because of the strong association between 
cervical cancer and HPV infection, several HPV type-speciﬁ  c 
vaccines are being developed. Early results suggest that these 
vaccines can prevent almost 100% of persistent infections with 
the relevant HPV type, raising the possibility of reducing the 
incidence of cervical cancer by prophylactic vaccination. But 
what would the impact of such vaccines be in countries that 
already have cervical cancer screening programs? To ﬁ  nd out, 
Ruanne Barnabas and colleagues have developed a dynamic 
transmission model of HPV 16 infection and progression to 
cervical cancer using epidemiological data from Finland. Their 
analyses indicate that high coverage of women alone over many 
decades with a vaccine that provides long-term protection 
would greatly reduce type-speciﬁ  c cancer incidence, a reduction 
that would be maximized by combining vaccination with routine 
screening.
The researchers’ model is represented by a ﬂ  ow chart in which 
susceptible women acquire an HPV infection that, in most cases, 
is cleared by their immune system. In some women, persistent 
infection induces precancerous lesions that can progress to 
invasive cervical cancer, regress spontaneously, or be screened 
and treated. HPV infection in men is represented by a simpler 
ﬂ  ow chart—they simply become infected and then develop 
immunity. The researchers incorporated values for parameters 
such as sexual activity, screening protocols, and treatment 
rates obtained from published Finnish studies in their model 
and calibrated it using historical data on the proportion of the 
Finnish population with antibodies to HPV 16. 
To allow them to model how vaccination will affect the 
incidence of cervical cancer, Barnabas and colleagues ﬁ  rst 
estimated the transmission probability of HPV in the Finnish 
population. This probability provides a measure of how easily 
HPV spreads—if it were 1.0, every sexual partnership a woman 
had with a man infected with HPV would result in her also 
becoming infected. The researchers’ transmission probability 
estimate of 0.6 is high, which indicates that universal coverage 
with a very effective vaccine will be needed to eliminate HPV 
infection in the population. The researchers put this value (which 
is subject to great uncertainty) and estimated values for age at 
sexual debut and the annual number of sexual partners into their 
model; they also assumed that vaccination takes place before 
sexual debut, is 100% effective, and gives life-long protection. 
The model predicts that vaccinating both men and women 
will be little better than vaccinating women alone, irrespective of 
whether vaccine coverage is high or low. Furthermore, although 
vaccinating 90% of young women before sexual debut could 
decrease HPV type-speciﬁ  c cervical cancer incidence by 91%, 
delaying vaccination until after sexual debut could decrease 
the impact of vaccination. The model also predicts that if 90% 
of women were vaccinated without screening, there would 
be 0.6 cases of cervical cancer per 100,000 women per year 
(compared with seven out of 100,000 with no intervention); 
vaccination plus screening every ﬁ  ve years would reduce 
this incidence further, by two-thirds. Finally, the researchers 
investigated how the duration of vaccine-conferred protection 
might affect invasive cervical cancer rates. The model predicts 
that—unintuitively—short-lived protection will marginally 
increase cervical cancer rates compared with no vaccination if, 
as some people believe, older women are more susceptible to 
the persistent HPV infections that progress to cervical cancer 
than are younger women. Booster vaccinations would avoid this 
potential problem. 
The researchers conclude that the most effective strategy 
for the reduction of cervical cancer in developed countries in 
which incidence is already low is widespread vaccine coverage 
(both in terms of the HPV type targeted and the fraction of 
the population vaccinated), combined with current screening 
protocols. Whether this recommendation is adopted will depend 
on how vaccines perform in ongoing phase III trials and on a 
detailed economic assessment of the options available.
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